Group 1 - The overall score for Cambrian (U688256) is 34.67, indicating a weak performance [1] - The main cost analysis shows the following prices: current main cost at 553.98 CNY, 5-day main cost at 539.33 CNY, 20-day main cost at 569.71 CNY, and 60-day main cost at 627.98 CNY [1] - In the past year, the stock has hit the upper limit 5 times and has not hit the lower limit [1] Group 2 - The short-term resistance level is at 547.47 CNY, while the short-term support level is at 523.50 CNY [2] - The stock price has broken through the short-term resistance level, indicating potential short-term strength, while the medium-term trend remains unclear [2] - On July 11, 2025, the net inflow of main funds was 114,177.99 million CNY, accounting for 18% of the total transaction amount [2]

Group 1 - The market has not shown any signals indicating the end of the upward trend, and the recent fluctuations are seen as a consolidation behavior, suggesting that the market can continue to rise next week [1][2] - Despite the pullback in the major indices, there has been no significant outflow of capital from the market, indicating that buying pressure remains strong [1] - The market is still above the 5-day moving average and key breakout levels, which supports the continuation of the upward trend [1] Group 2 - The recent pullback is primarily observed in the banking sector, which has experienced significant gains recently, while other sectors such as metals, brokerage, rare earths, and pharmaceuticals continue to show upward momentum [2] - The presence of strong buying interest in various sectors suggests that the overall market trend is not ending, but rather experiencing a temporary correction [2] - The current market behavior is characterized as a short-term consolidation, with expectations for further upward movement in the coming week [2]

Group 1 - The stock of Baike Biological (688276) has a comprehensive score of 60.55, indicating a strong performance [1] - The main cost analysis shows that the current main cost is 21.78 CNY, with a 5-day main cost of 21.40 CNY, a 20-day main cost of 20.99 CNY, and a 60-day main cost of 20.94 CNY [1] - Over the past year, the stock has not experienced any limit-up or limit-down events [1] Group 2 - On July 11, 2025, the stock saw a net outflow of 55.92 thousand CNY in main funds, which is -1% of the total transaction amount [2] - The stock has a short-term resistance level at 21.58 CNY and a support level at 21.05 CNY, indicating potential for short-term strength if the resistance is broken [2] - The stock is associated with several sectors, including bioproducts (1.53%), virus prevention (0.59%), state-owned enterprise reform (0.51%), and biovaccines (0.70%) [2]

Group 1 - The stock of Wealth Trend (688318) has a comprehensive score of 55.72, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 115.60 CNY, 5-day main cost at 108.76 CNY, 20-day main cost at 107.99 CNY, and 60-day main cost at 100.80 CNY [1] - In the past year, the stock has hit the upper limit of trading three times and has not hit the lower limit [1] Group 2 - Northbound capital data indicates a holding of 1.0691 million shares, accounting for 0.58% of the circulating shares, with a net purchase of 168,800 shares yesterday [1] - The short-term pressure level is at 108.47 CNY, while the short-term support level is at 102.95 CNY; the stock price has broken through the short-term pressure level, suggesting potential short-term strength [2] - The net inflow of main funds on July 11, 2025, was 167.79 million CNY, accounting for 11% of the total transaction amount [2]

Group 1 - The stock of Aerospace Technology (688239) has a comprehensive score of 58.37, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 33.91 CNY, 5-day main cost at 33.69 CNY, 20-day main cost at 33.01 CNY, and 60-day main cost at 31.83 CNY [1] - In the past year, the stock has not experienced any limit-up or limit-down events [1] Group 2 - The short-term pressure level is at 34.28 CNY, while the short-term support level is at 33.11 CNY [2] - The mid-term pressure level is at 34.98 CNY, and the mid-term support level is at 30.77 CNY [2] - The current short-term and mid-term trends are unclear, awaiting direction from main funds [2][3] Group 3 - On July 11, 2025, the net outflow of main funds was 744.42 million CNY, accounting for -5% of the total transaction amount [2] - The breakdown of fund flows includes a net outflow of 453.63 million CNY from large orders and 290.79 million CNY from super large orders, while retail investors saw a net inflow of 89.21 million CNY [2][3] - The stock is associated with industries such as aerospace (0.57%), commercial aerospace (0.29%), large aircraft (0.40%), and western development (0.35%) [2] Group 4 - The latest financial data shows earnings per share at 0.29 CNY, operating profit at 0.51 billion CNY, and a net profit of approximately 46.37 million CNY [2][3] - The sales gross margin is reported at 26.229% [2][3]

Group 1 - The stock of Transsion Holdings (688036) has a comprehensive score of 48.35, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 75.44 yuan, with a 5-day cost of 76.05 yuan and a 20-day cost of 77.28 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - The short-term pressure level is at 77.36 yuan, while the short-term support level is at 74.63 yuan [2] - The K-line pattern indicates a long upper shadow, suggesting heavy pressure at the upper levels and a blocked upward trend [2] - On July 11, 2025, the net inflow of main funds was 15.61 thousand yuan, with a significant net inflow of 993.65 thousand yuan from large orders [2]

Core Viewpoint - The stock of XD Yingtong (688080) is currently showing a weak performance with a comprehensive score of 47.54, indicating uncertainty in both short-term and mid-term trends, awaiting direction from major funds [1][2]. Price and Cost Analysis - The current main cost is 46.53 CNY, with a 5-day main cost of 47.25 CNY, a 20-day main cost of 47.53 CNY, and a 60-day main cost of 45.46 CNY [1]. - The stock has not experienced any limit-up or limit-down events in the past year [1]. Technical Analysis - Short-term pressure level is at 48.39 CNY, while short-term support level is at 46.32 CNY [2]. - Mid-term pressure level is at 50.69 CNY, and mid-term support level is at 45.76 CNY [2]. - No special K-line patterns are observed at this time [2]. Fund Flow Data - On July 11, 2025, the net outflow of major funds was 357.65 thousand CNY, accounting for 8% of the total transaction volume [2]. - The net outflow from super large orders was 152.55 thousand CNY, and from large orders was 205.10 thousand CNY, while retail investors saw a net outflow of 11.76 thousand CNY [2]. Financial Data - The latest financial report indicates earnings per share of 0.302 CNY, operating profit of 0.32 billion CNY, and a net profit of 22,894,941.58 CNY [3]. - The sales gross margin stands at 49.824% [3]. Related Industries/Concepts - The stock is associated with sectors such as communication equipment (0.45%), edge computing (0.82%), industrial internet (0.96%), and the Internet of Things (0.55%) [4].

Group 1 - The stock of Xingqiu Graphite (688633) has a comprehensive score of 58.43, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 27.97 yuan, 5-day main cost at 27.65 yuan, 20-day main cost at 26.99 yuan, and 60-day main cost at 27.34 yuan [1] - The stock has not experienced any limit-up or limit-down events in the past year [1] Group 2 - The short-term resistance level is set at 28.01 yuan, while the short-term support level is at 26.89 yuan [2] - The mid-term resistance level is at 26.18 yuan, and the mid-term support level is currently unclear, awaiting direction from main funds [2] - The K-line pattern indicates a bullish signal, suggesting potential upward movement from the bottom, continuation in the middle, and a composite top signal at the peak [2] Group 3 - On July 11, 2025, the net inflow of main funds was 52.59 thousand yuan, accounting for 2% of the total transaction volume [2] - Large orders showed a net inflow of 52.59 thousand yuan, while retail investors experienced a net outflow of 13.53 thousand yuan [2] - Related industry sectors include specialized equipment (0.53%), phosphorus chemical industry (0.15%), new materials (0.39%), and intellectual property (1.00%) [2]

Group 1 - The stock of DeMa Technology (688360) has a comprehensive score of 57.68, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 19.31 yuan, 5-day main cost at 19.09 yuan, 20-day main cost at 18.35 yuan, and 60-day main cost at 17.97 yuan [1][2] - The stock has experienced no limit-up occurrences and one limit-down occurrence in the past year [1] Group 2 - Short-term resistance is at 19.60 yuan, while short-term support is at 18.31 yuan; the mid-term resistance is at 16.85 yuan, and mid-term support is currently unclear [2] - As of July 11, 2025, the net inflow of main funds is 22.96 million yuan, accounting for 10% of the total transaction volume [2] - The financial data indicates earnings per share of 0.17 yuan, operating profit of 0.43 billion yuan, and a sales gross margin of 32.119% [3][2] Group 3 - The stock is associated with various sectors, including General Equipment (0.54%), Digital Twin (0.66%), Lithium Battery (0.11%), and Artificial Intelligence (0.83%) [4]

Group 1 - The stock of Nuotai Bio (688076) has a comprehensive score of 52.17, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 38.88 CNY, 5-day main cost at 38.12 CNY, 20-day main cost at 37.85 CNY, and 60-day main cost at 37.20 CNY [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - On July 11, 2025, the net inflow of main funds was 136.09 million CNY, accounting for 16% of the total transaction volume [2] - The stock's earnings per share (EPS) is 0.69 CNY, with an operating profit of 178 million CNY and a net profit of approximately 147.87 million CNY [2][3] - The sales gross margin stands at 70.204% [2][3] Group 3 - The stock is associated with several industry sectors, including medical services (1.48%), CRO (Contract Research Organization) (2.56%), influenza (0.63%), and hepatitis concepts (0.68%) [2][3] - Short-term and mid-term trends are currently unclear, with the market awaiting direction from main funds [2][3]